April 16, 2020 —Intelerad Medical Systemsannounced that the U.S. Food and Drug Administration (FDA) has cleared itsInteleConnect EV solutionfor diagnostic image review on a range of mobile devices. Approval of Intelerad’s 510(k) submission comes at acritical timefor healthcare systems and ensures that radiologists are able to collaborate and leverage resources in more creative ways, even when workstation access is not available.
Now, in addition to use on mobile devices for clinical purposes, InteleConnect EV is approved for mobile diagnostic image review as well. It can immediately be used on various iPad and iPhone models, with additional devices to follow. The FDA clearance comes as part of a recertification of the diagnostic functionality for Intelerad’s flagship product,IntelePACS.
The ability to review images and collaborate with clinical staff through diagnostic radiology is key to ensuring the best possible patient outcomes, in any context. With mobile access to diagnostic quality images via InteleConnect EV, radiologists have the freedom to collaborate anytime, anywhere.
“For more than 20 years, Intelerad has provided innovative solutions that enable radiologists to deliver highly accurate diagnoses, at optimum productivity,” saidRick Rubin, Intelerad founder and chief engineering officer. “While a mobile device is not a replacement for a diagnostic workstation, this clearance offers powerful new flexibility for accessing diagnostic quality images with InteleConnect EV, even when radiologists are outside their standard work environments.”
除了用于普遍安全查看的Intelerad EV, Intelerad TeleDiagnostics还可以快速、安全地部署到现有的基础设施中，以支持客户的远程诊断和临床协作工作流需求。
For more information:www.intelerad.com
August 01, 2022
